Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: Report of three cases

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1184-1188

  Khanna, Dinesh ^a   Agrawal, Harsh ^a   Clements, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti tumour necrosis factor antagonists; Case report; Case series; Eosinophilic fasciitis; Infliximab

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EOSINOPHILIC FASCIITIS; FEMALE; HUMAN; HUMAN TISSUE; JOINT CONTRACTURE; PRIORITY JOURNAL; REMISSION; RETREATMENT; SKIN BIOPSY; SKIN MANIFESTATION; SKINFOLD; SORE THROAT; SYMPTOM; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; EOSINOPHILIA; FASCIITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PREDNISONE; STEROIDS; TREATMENT OUTCOME;

EID: 77953488664     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq062     Document Type: Article

References (21)

1. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1984;11:569-70.
2. Eosinophilic fasciitis. Br Med J 1980;280:506.
3. Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 1996;18: 465-73.
4. Jensen E, Hess B, Hunziker T, Roos F, Helbling A. Eosinophilic fasciitis (Shulman syndrome). Schweiz Med Wochenschr 2000;130:156-60.
5. Mosconi S, Streit M, Bronimann M, Braathen LR. Eosinophilic fasciitis (Shulman syndrome). Dermatology 2002;205:204-6.
6. Romero AG, Fernandez JG, Calatayud JC. Eosinophilic fasciitis associated with simple traumatism. Acta Dermatovenerol Croat 2001;9:287-90.
7. Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 2002;61:1111-2.
8. Minciullo PL, Morabito F, Mandaglio R, Iacopino P, Gangemi S. Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: report of two cases. Clin Rheumatol 2006; 25:80-2.
9. Yamanishi Y, Ishioka S, Yamakido M. Complete remission of relapsing eosinophilic fasciitis associated with bronchial asthma following regular steroid inhalation. Rheumatology 2000;39:339-40.
10. Valencia IC, Chang A, Kirsner RS, Kerdel FA. Eosinophilic fasciitis responsive to treatment with pulsed steroids and cyclosporine. Int J Dermatol 1999;38: 369-72.
11. Bonnotte B, Chauffert B, Caillot D, Martin F, Lorcerie B. Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. Br J Rheumatol 1998;37: 1358-9.
12. Bukiej A, Dropinski J, Dyduch G, Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol 2005;24:634-6.
13. Pouplin S, Daragon A, Le LX. Treatment of eosinophilic fasciitis with methotrexate. J Rheumatol 1998;25:606-7.
14. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151-7.
15. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005;9: 296-302.
16. Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999;14:47-51.
17. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63: 48-56.
18. Denton CP, Engelhart M, Tvede N et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009;68:1433-9.
19. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7.
20. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7: 382-6.
21. Tzaribachev N, Holzer U, Schedel J, Maier V, Klein R, Kuemmerle-Deschner J. Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology 2008;47: 930-2.